Nov 09, 2023 / 06:00PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at UBS. Thank you so much for joining us here at the UBS Biopharma Conference in Miami. Very happy to have Amicus Therapeutics here with us today for a fireside chat.
Joining us from Amicus is Jeff Castelli, Chief Development Officer. Thanks so much for making the trip to Miami. Maybe just to kick it off, you guys reported earnings yesterday, including first sales in Pompe. So talk a little bit about that.
Jeffrey P. Castelli - Amicus Therapeutics, Inc. - Chief Development Officer
Yes. Thank you, Ellie. Thanks to the UBS team for having us. We're happy to be here. Yes, we just had third quarter earnings yesterday. Very excited to give an update on the launch of Pombiliti and Opfolda in Pompe. As a reminder, we just recently received approval in July in Europe, in August in the U.K. and here at the end of September in the U.S. And I'm really excited by early days of launch. We said that we're well on track to
Amicus Therapeutics Inc at UBS BioPharma Conference Transcript
Nov 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers